On May 28, 2026 Massive Bio, a global leader in AI-enabled oncology trial access and precision oncology navigation, reported that it will unveil the next phase of Reticulum Nexus, its trusted multi-agent oncology intelligence ecosystem, during the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Reticulum Nexus is designed to address one of oncology’s most persistent failures: the gap between the rapid pace of cancer innovation and the ability of patients, physicians, trial sites, and sponsors to coordinate action in real time. The platform connects patient engagement, medical record ingestion, eligibility interpretation, clinical trial pre-screening, physician referral orchestration, biomarker intelligence, site activation, patient navigation, and longitudinal follow-up into a single AI-enabled operating layer.

"Cancer patients are not lost because science is absent. They are lost because the system around them is fragmented," said Selin Kurnaz, PhD, Co-Founder and CEO of Massive Bio. "Reticulum Nexus was built to make oncology access coordinated, measurable, trusted, and fast. We are moving from point solutions to infrastructure."

The ASCO (Free ASCO Whitepaper) announcement builds on several recent Massive Bio milestones: the company’s collaboration with OpenAI to transform complex trial criteria into structured, machine-readable parameters for AI-enabled pre-screening; its collaboration with the American Cancer Society’s ACS ACTS program to expand equitable clinical trial access nationally; its DiMe Seal and CMS Medicare App Library listing; and the publication of peer-reviewed prospective evidence demonstrating AI-driven trial matching at scale.

From Trial Matching to Oncology Orchestration

For years, cancer trial access has been treated as a search problem: find a patient, find a protocol, compare eligibility, and generate a match. But in real-world oncology, matching is only the beginning. Patients need records collected, eligibility clarified, biomarkers interpreted, physicians engaged, referrals routed, sites activated, social barriers addressed, and follow-up maintained.

Reticulum Nexus is designed to orchestrate those steps through coordinated AI agents and human-in-the-loop workflows. The ecosystem brings together Patient Connect, the patient-facing digital front door for record upload, trial matching, and care coordination; TrialRelay, the physician-facing referral orchestration platform powered by the TrialRouter AI agent; NexusPulse, the real-time AI signal engine that turns consented real-world data into prioritized next-best actions; DrArturo AI, the clinician-facing oncology intelligence agent; Phoebe AI, the patient-facing navigation intelligence agent; and Sentinel Agents, a family of monitoring agents designed to detect critical clinical, operational, equity, safety, and biomarker signals earlier in the patient journey.

"Reticulum Nexus is not a chatbot and it is not a dashboard," said Arturo Loaiza-Bonilla, MD, MSEd, FACP, Co-Founder and Chief Medical AI Officer of Massive Bio. "It is a multi-agent oncology operating system. It understands context, detects urgency, routes action, supports clinicians, engages patients, and keeps the workflow moving until the loop is closed."

Built on Trust, Evidence, and National Reach

The next phase of Reticulum Nexus is being launched at a time when oncology AI is moving from experimentation to operational deployment. Massive Bio’s April 2026 collaboration with OpenAI is focused on AI-powered protocol parameterization and pre-screening, allowing complex clinical trial criteria from sponsors and public registries to be transformed into structured, machine-readable parameters.

The company’s platform has earned the DiMe Seal and is listed in the CMS Medicare App Library, a trusted centralized directory where Medicare beneficiaries can discover vetted digital health options that have undergone review for security, privacy, clinical evidence, usability, and equity. The Medicare.gov App Library lists Massive Bio Patient Navigator as helping cancer patients find and access matched clinical trials and personalized care options based on diagnosis, genomic profile, and treatment history.

Through the American Cancer Society’s ACS ACTS program, ACS is working with Massive Bio for AI-driven clinical trial matching services to bring patients tailored options and support resources, including education, cancer information specialist support, transportation, lodging, and other needs-based assistance.

Massive Bio’s recent peer-reviewed prospective study reported that its neuro-symbolic, multi-agent AI platform matched cancer patients to clinical trials four times faster than conventional methods, across 3,804 patients, more than 157,000 clinical document pages, and more than 17,000 oncologist-confirmed trial matches.

"Trust is the multiplier," said Selin Kurnaz. "AI in oncology cannot scale on novelty alone. It must be evidence-based, privacy-aware, interoperable, auditable, and grounded in real patient workflows. That is why Reticulum Nexus is being built not just as technology, but as infrastructure."

ASCO Demonstration: The Closed-Loop Oncology Journey

At ASCO (Free ASCO Whitepaper) 2026, Massive Bio will demonstrate how Reticulum Nexus can coordinate a patient journey from first engagement to trial activation. A patient may enter through Patient Connect, provide consent, and upload records. DrArturo AI can help structure the clinical context. OpenAI-enabled parameterization can support protocol interpretation and pre-screening. NexusPulse can detect urgency, trial opportunity, biomarker gaps, or access friction. Sentinel Agents can monitor clinical, referral, safety, and equity signals. TrialRelay can route physician-to-physician handoffs. Phoebe AI can support patient education, navigation, and follow-up. ACS ACTS resources can help address support needs.

The result is a coordinated, human-in-the-loop infrastructure designed to help patients move from possibility to action.

"Massive Bio is turning clinical trial access from a search problem into a real-time orchestration problem," said Dr. Loaiza-Bonilla. "The science is there. The patients are there. What has been missing is the operating system that connects them. That is Reticulum Nexus."

(Press release, Massive Bio, MAY 28, 2026, View Source [SID1234666147])

On May 28, 2026 Bold Therapeutics, a clinical-stage biopharmaceutical company founded to develop and commercialize novel metallotherapeutics, reported data to support the neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for the treatment of patients with advanced gastrointestinal cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This data is presented in an abstract as part of the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place in Chicago from May 29th to June 2nd.

Abstract title: Neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for the treatment of advanced gastrointestinal cancers.
Authors: Grainne M. O’Kane, Elena Elimova, Jennifer L. Spratlin, Rachel A. Goodwin, Elaine McWhirter, Petr Kavan, Joel R. Hecht, Dae Won Kim, Do-Youn Oh, Sun Young Rha, Seung Tae Kim, Moon Ki Choi, Dong-Hoe Koo, Mark Bazett, Malcolm Snow, Michelle A. Jones, Jim Pankovich

Abstract #: e15029
View Source

Summary

Results: 109 participants with advanced gastrointestinal cancer were evaluated in the study and all but one had prior chemotherapy in the advanced setting. 95% were previously treated with oxaliplatin (65%) or cisplatin (30%). 45 patients (41%) had prior neuropathy. On study, 24 patients (22%) experienced at least one oxaliplatin-induced peripheral neuropathy (OIPN) adverse event. Lower OIPN incidence was observed across all cohorts relative to benchmarks: mCRC (14% vs. 53%), BTC (32% vs. 68%), GC (19% vs. 63%), and pancreatic cancer (29% vs. 38%). Only 9 patients (8.2%) discontinued oxaliplatin, with only 2 attributed to OIPN. Of 69 dose reductions, 16 (23%) were due to OIPN. Patients at the highest BOLD-100 dose level (625 mg/m2) had the lowest OIPN incidence.

Conclusions: Analysis of safety and dosing data from this study suggests a potential neuroprotective effect of BOLD-100 against oxaliplatin-induced peripheral neuropathy.

Bold Therapeutics is currently advancing BOLD-100 through a global Phase 2 randomized controlled trial across sites in Canada, European Union, and South Korea. This trial is investigating BOLD-100’s anticancer efficacy, but also includes important quality of life questionnaires focused on its neuroprotective potential. Please visit ClinicalTrials.gov for more information (NCT04421820).

(Press release, Bold Therapeutics, MAY 28, 2026, View Source [SID1234666163])

On May 28, 2026 RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, reported its upcoming participation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30 to June 2 in Los Angeles, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the meeting, RadioMedix leadership will participate in two sessions highlighting the Company’s work in targeted alpha therapy and lead-212 (²¹²Pb) radiopharmaceutical development.

Ebrahim S. Delpassand, M.D., Chief Executive Officer and Founder of RadioMedix, will participate in an Emerging Technology session focused on the production and clinical use of alpha emitters, where he will discuss the potential role of ²¹²Pb in radiopharmaceutical development.

Izabela Tworowska, Ph.D., MS.Pharm, Chief Scientific Officer, Co-Founder and Board Member of RadioMedix, will present during the Oncology: Discovery & Translational Meet-the-Author Session, highlighting preclinical evaluation of ²¹²Pb-RMX-VH-PKM, a second-generation LDLR-targeting radioconjugate co-developed with Vect-Horus for pancreatic ductal adenocarcinoma (PDAC). The presentation will include data on biodistribution, dose-dependent tumor response, survival, and preliminary tolerability in preclinical PDAC models.

In addition, Dr. Delpassand will participate in the 2026 IBA KOL Meeting, hosted by IBA RadioPharma Solutions during SNMMI week, on Saturday, May 30.

RadioMedix’s participation at SNMMI 2026 coincides with the Company’s 20th anniversary, marking a meaningful moment in its evolution as the broader radiopharmaceutical field continues to gain momentum. Since its founding in 2006, RadioMedix has helped shape the growth of radiopharmaceuticals through early clinical leadership in radioligand therapy, development of infrastructure across isotope supply and manufacturing, and contributions to foundational programs that have helped define the field.

"SNMMI has long been an important forum for scientific exchange and progress in nuclear medicine, making it a meaningful setting to share our latest work and mark RadioMedix’s 20-year journey," said Dr. Delpassand. "When we founded RadioMedix, our goal was to help bring the promise of targeted radiopharmaceuticals closer to patients with difficult-to-treat cancers. Over the past two decades, that mission has guided our work across discovery, isotope supply, manufacturing, and clinical development, and it continues to shape how we approach the future of targeted radiopharmaceutical innovation."

Today, RadioMedix continues to advance precision solutions in nuclear medicine with a focus on diagnostics and targeted therapies for cancers with high unmet need. The Company’s work spans radiopharmaceutical discovery and development, isotope generation, radiochemistry, translational research, and GMP production through the SPICA Center, its 27,000 sq. ft. radiopharmaceutical manufacturing facility.

"At RadioMedix, our scientific work has always been closely tied to patient need," said Dr. Tworowska. "Our participation at SNMMI this year is an opportunity to share progress from our team, engage with the broader nuclear medicine community, and recognize the importance of continued innovation in targeted radiopharmaceuticals. This year’s SNMMI meeting is especially meaningful for us as our company celebrates 20 years of innovation in radiopharmaceutical development and clinical translation."

Presentation Details
Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting

Emerging Technology Session
Session: ET03: Alpha 2: At-211 and Pb-212 (Non-CE)
Date: June 1, 2026
Session Time: 2:15 p.m. to 3:30 p.m. PT
Presentation: Pb-212: Clinical Use
Presentation Time: 2:25 p.m. to 2:35 p.m. PT
Location: 511ABC, Convention Center
Presenter: Ebrahim S. Delpassand, M.D., Chief Executive Officer and Founder, RadioMedix

Poster Presentation / Meet-the-Author Presentation
Title: Homing alpha-emitter therapy to pancreatic ductal cancer using 212Pb–labeled LDLR-targeting peptide
Session: MTA11: Oncology: Discovery & Translational Meet-the-Author Session
Date: June 2, 2026
Time: 11:30 a.m. to 12:15 p.m. PT
Location: Science Pavilion – South Hall GHJK (Convention Center)
Abstract Number: 262146
Screen: 43
Presenter: Izabela Tworowska, Ph.D., MS.Pharm, Chief Scientific Officer, Co-Founder and Board Member, RadioMedix

(Press release, RadioMedix, MAY 28, 2026, View Source [SID1234666179])

On May 28, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, reported the closing of its previously announced marketed public offering of units (the "Units") of the Company at a price to the public of CDN$0.50 per Unit (the "Offering"), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds the Company may receive from the exercise of the underlying warrants. Pursuant to the Offering, the Company issued a total of 8,880,000 Units. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company (a "Warrant Share") at an exercise price of $0.65 per Warrant Share until the date that is three years following the initial closing date of the Offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Offering was made pursuant to an agency agreement (the "Agency Agreement") entered into between Bloom Burton Securities Inc., as sole agent (the "Agent"), and the Company dated May 21, 2026. An aggregate of 450,100 compensation warrants of the Company (each, a "Broker Warrant") were issued by the Company in connection with the Agency Agreement, each Broker Warrant entitling the holder to acquire one common share of the Company at an exercise price of $0.50 per share until the date that is two years following the initial closing date of the Offering.

The Offering was made pursuant to a prospectus supplement (the "Prospectus Supplement") dated May 21, 2026 to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the "Base Shelf Prospectus") filed in the Provinces of British Columbia, Alberta and Ontario. The Units may also be offered in certain other jurisdictions outside of Canada, provided that a placement therein does not give rise to any prospectus, registration or continuous disclosure obligations on the part of the Company.

The Base Shelf Prospectus, the Agency Agreement and the Prospectus Supplement are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

The securities of the Company described above have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any U.S. state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the "United States" or "U.S. Persons" (as such terms are defined in Regulation S under the 1933 Act) except pursuant to an effective registration statement under the 1933 Act and applicable U.S. state securities laws or an available exemption from the registration requirements of the 1933 Act and applicable U.S. state securities laws.

In addition to the above Offering and as announced previously, the Company has entered into a separate structured financing of CDN$8.0 million with Sorbie Bornholm LP and Sorbie Investments LLP ("Sorbie").

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Medicenna Therapeutics, MAY 28, 2026, View Source [SID1234666148])

On May 28, 2026 Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) reported that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting, which is being held from May 29-June 2, 2026, in Chicago, IL. The abstract titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors" has been published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track and can be viewed on the ASCO (Free ASCO Whitepaper) website (View Source).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract reports the findings from an ongoing first-in-human study of LNP8701 in patients with solid tumors. LNP8701 is an orally administered, investigational SOS1 (Son of Sevenless1) inhibitor, designed to block SOS1-mediated RAS activation, thereby limiting oncogenic signaling that promotes tumor growth. Results indicate that LNP8701 was well tolerated with desirable safety, pharmacokinetics profile and favorable anti-tumor activity. The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles (i.e., 1 year) and one patient completed 14 cycles with stable disease.

Vinita Gupta, CEO, Lupin, said, "The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers. We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes."

Current data suggest that LNP8701 is safe and well-tolerated across all tested dosing levels. Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination.

Details of the Abstract:

Abstract Number: e15162
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Citation: J Clin Oncol 44, 2026 (suppl 16; abstr e15162)
DOI: 10.1200/JCO.2026.44.16_suppl.e15162
Clinical Trial Registration Number: CTRI/2024/08/072373
Abstract link: View Source

(Press release, Lupin, MAY 28, 2026, View Source [SID1234666164])